AstraZeneca hands off epilepsy programs to Ovid; Amylyx scores priority review for ALS drug 

Still recovering from a setback in its lead program, Ovid Therapeutics has turned to AstraZeneca for a suite of experimental epilepsy drugs.

Ovid is paying the Big Pharma partner $5 million in cash and $7.5 million in stock to access a library of early-stage small molecules...

Click to view original post